Mode
Text Size
Log in / Sign up
N/A N=14,986

Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany

Arterial Hypertension

Enrolled (actual)
14,986
Serious AEs
5.8%
Results posted
Aug 2014
Primary outcome: Primary: Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) — 11.8; 9.7; 9.9 percent change

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Aliskiren (Drug); ACE-I/ARB (Drug); No RAS-inhibition (Drug)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Stiftung Institut fuer Herzinfarktforschung
Primary completion
Oct 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)
12.0; 8.9; 9.4
PRIMARY
Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP)
9.1; 6.2; 6.4
PRIMARY
Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)
12.0; 8.9; 9.4
PRIMARY
Efficacy of Hypertension Treatment on Diastolic Office Blood Pressure (DBP)
10.3; 8.5; 8.9
PRIMARY
Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP)
12.0; 8.9; 9.4
PRIMARY
Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP)
9.1; 6.2; 6.4
SECONDARY
Therapy Adherence Regarding Drug Treatment
65.8; 82.1; 60.7
SECONDARY
Therapy Adherence Regarding Drug Treatment
65.8; 82.1; 60.7
SECONDARY
Therapy Adherence Regarding Drug Treatment
65.8; 82.1; 60.7
SECONDARY
Adverse Events
12.9; 12.6; 9.5
SECONDARY
Adverse Events
12.9; 12.6; 9.5
SECONDARY
Adverse Events
12.9; 12.6; 9.5
SECONDARY
Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement
7.9; 6.1; 7.3
SECONDARY
Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement
5.4; 5.3; 6.4
SECONDARY
Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement
7.9; 6.1; 7.3
SECONDARY
Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement
5.4; 5.3; 6.4
SECONDARY
Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement
7.9; 6.1; 7.3
SECONDARY
Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement
5.4; 5.3; 6.4
SECONDARY
Influence of Anti-hypertensive Treatment on Renal Function
32.7; 28.2; 28.6
SECONDARY
Influence of Anti-hypertensive Treatment on Renal Function
32.7; 28.2; 28.6
SECONDARY
Influence of Anti-hypertensive Treatment on Renal Function
32.7; 28.2; 28.6

Summary

In Germany nearly half of the population present elevated values of blood pressure, with - as a result of lifestyle factors and a growing average age - further increasing numbers. Consequences of arterial hypertension may be cardiovascular diseases, cerebrovascular events, and renal insufficiency. Thus, hypertension therapy focuses on the reduction of these complications. The aims of the 3A-registry are the characterization of outpatients with hypertension, their diagnostic procedures and medical treatment (esp. with renin inhibitors), therapy compliance and success, clinical events, and an assessment of overall guideline adherence in the treatment of these patients. Patients fulfilling the relevant criteria are enrolled and followed up by their general practitioner or medical specialist.

Eligibility Criteria

Inclusion Criteria

  • treatment as outpatient
  • arterial hypertension
  • treatment with a renin inhibitor, ACE inhibitor, ARB, or without RAS blockade
  • informed consent

Exclusion Criteria

  • foreseeable difficulties to perform follow up
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01454583). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search